The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient | PLOS ONE
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma - eBioMedicine
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia | PNAS
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy: Trends in Cancer
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
Survival of patients with p53 mutations in the DNA-binding motifs... | Download Scientific Diagram
Impact of TP53 mutations in Triple Negative Breast Cancer | npj Precision Oncology
An unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation | Science Advances
Frequency of p53 mutations in human cancers. (A) Schematic picture... | Download Scientific Diagram
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
IJMS | Free Full-Text | The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer
Frontiers | Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
Targeting a neoantigen derived from a common TP53 mutation | Science
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
p53 Is the Most Frequently Mutated Gene in Cancer, but Can We Target It?
p53 Is the Most Frequently Mutated Gene in Cancer, but Can We Target It?
Pathogenesis of TP53-mutated Acute Myeloid leukemia | Laboratory of Daniel C. Link, M.D. | Washington University in St. Louis
Frontiers | Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Cancers | Free Full-Text | Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density | npj Breast Cancer
